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A variety of innate defense factors in saliva such as lysozyme and lactoferrin contribute to mucosal
protection and modulate Candida populations in the oral cavity. It is also known that in human immunode-
ficiency virus (HIV)-infected individuals significant variations in the concentrations of lysozyme and lactofer-
rin in saliva occur during disease progression. Therefore, the aim of this study was to determine the in vitro
susceptibility to human lactoferrin and hen egg white lysozyme of genotypically similar oral Candida albicans
isolates obtained from six HIV-infected ethnic Chinese during sequential visits over a 12-month period. The
similarity of the genotypes (50 in total) was evaluated using a randomly amplified polymorphic DNA assay. A
blastospore viability assay was performed to evaluate the sensitivity of the organisms to lysozyme and
lactoferrin. Exposure to physiological concentrations of either lysozyme (30 g/ml) or lactoferrin (20 g/ml)
caused a rapid loss of viability among all isolates to a varying extent. None of the sequential C. albicans isolates
demonstrated significant differences in sensitivity to either protein from one visit to the next; similar results
were noted when the different genotypes from the same individual were compared. On Spearman correlation
analysis of two genotypes that were sequentially isolated from a single patient, a significant negative correlation
between lysozyme (r  0.88; P < 0.02) (but not lactoferrin) resistance and the duration of HIV disease was
seen. These results imply that a minority of C. albicans isolates that persist intraorally in individuals with HIV
disease develop progressive resistance to innate salivary antifungal defenses such as lysozyme, possibly as an
adaptive response. However, the vast majority of the Candida isolates appear to succumb to these nonspecific
host immune mediators abundantly present in the oral environment.
Candida albicans is the main cause of oral candidiasis in
patients with human immunodeficiency virus (HIV) infection
and AIDS (13, 38). Almost 90% of AIDS patients suffer from
oropharyngeal or esophageal candidiasis at some stage of their
disease (38). As HIV infection progresses, so does the oral
colonization by Candida, and it eventually becomes a perma-
nent oral resident despite prophylactic antifungal therapy (1,
36, 45). With the development of DNA fingerprinting methods,
it is now possible to investigate strain relatedness and emer-
gence of novel strains of C. albicans by sequentially sampling a
cohort of individuals either with or without symptomatic oral
candidiasis. Several authors have shown that AIDS patients are
frequently infected with the same C. albicans strains over re-
current episodes of oral thrush (5, 34, 47, 60), and others have
found, for instance in Candida vaginitis, that the same yeast
strain may persist through successive episodes of infection (48,
49). Although these and other studies have traced the yeast
genotypes over multiple infection episodes (29, 36, 45), not
many have investigated the phenotypic attributes of these ge-
netically similar strains that persist intraorally (43).
Lysozyme (also called muramidase) and lactoferrin are two
major nonimmunological antimicrobial proteins in saliva and
are thought to modulate Candida populations in the oral cavity
(39). A number of researchers including our group have inves-
tigated the in vitro fungicidal activity of lysozyme against sev-
eral Candida species (14, 25, 41, 42, 44, 55). These studies have
demonstrated a significant dose-, time-, and strain-dependent
killing effect when Candida species are exposed to lysozyme.
Lactoferrin, an iron-binding, acute-phase protein in saliva
(11, 54) has a demonstrable microbicidal or microbistatic effect
in vitro (8, 18, 59). Recently, in a series of studies we demon-
strated the anticandidal effect of iron-free apolactoferrin, ob-
tained from human colostrum (31, 44).
It is now known that HIV-infected individuals demonstrate
a significant reduction in salivary gland secretions (2, 3, 12, 15,
30, 46, 62). In one study, Muller et al. (30) noted that a
decreased output of parotid lactoferrin in parallel with mark-
edly reduced secretory immunoglobulin A (IgA) contributed
to the frequent oral infections observed in a group of HIV-
seropositive subjects (30). Nonetheless, others were unable to
detect significant differences in lactoferrin concentrations in
stimulated parotid saliva in HIV-infected subjects and healthy
controls (3, 24).
With regard to salivary lysozyme, many have reported ele-
vated lysozyme concentrations in HIV-infected individuals
with clinically detectable oral candidiasis (2, 3, 15, 23, 56, 62).
Although the quality and the quantity of these nonimmune
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defense proteins in HIV-infected patients have been investi-
gated, their contribution to the antifungal defenses of the oral
cavity during disease progression is virtually unknown.
We hypothesized that the high prevalence of C. albicans
and/or the incidence of oral candidiasis in HIV infection may
be due to the emergence of virulent strains of the yeast during
disease progression which may have acquired resistance to the
salivary defenses such as lactoferrin and lysozyme. Hence, the
main objective of this study was to evaluate and compare in
vitro the susceptibilities of genotypically similar sequential iso-
lates of C. albicans to two nonimmune defense factors of the
oral mucosal immune system, i.e., lysozyme and lactoferrin.
MATERIALS AND METHODS
Candida isolates and growth conditions. A total of 165 C. albicans isolates
were obtained from a cohort of HIV-infected individuals attending an outpatient
AIDS clinic during sequential therapy sessions over 1 year. The demographic
data for this patient cohort are shown in Table 1. The organisms were recovered
using the oral rinse technique of Samaranayake et al. (40). In brief, the patients
were requested to rinse the mouth for 60 s with 10 ml of phosphate-buffered
saline (pH 7.3, 0.1 M) supplied in a sterile universal container. The sample was
expectorated into the container and immediately transferred to the laboratory,
where the oral rinse was concentrated by spinning at 1,700  g for 10 min,
resuspended in 2 ml of sterile phosphate-buffered saline, and vortex mixed for
30 s. The concentrated oral rinse was then dispensed onto a Sabouraud dextrose
agar (SDA) plate in an archimedean spiral using a spiral plater (model DU;
Spiral Systems Inc., Cincinnati, Ohio). The plates were incubated for 48 h at
37°C, and up to five yeast colonies per sample were randomly chosen by a single
investigator (Y.H.S.) and subcultured onto SDA plates. The pure yeast cultures
were then harvested, suspended in water in sterile vials, and stored at 20°C.
The organisms were identified by the germ tube test, growth at 45°C, chlamy-
dospore formation, and API 20C AUX (Bio-Merieux, Marcy l’Etoile, France)
assimilation tests, and the phenotype was further defined using CHROMagar
Candida plates (CHROMagar, Paris, France) (33). Their identities were recon-
firmed using the new improved APILAB Plus (Bio-Merieux) assay to exclude
Candida dubliniensis. The yeasts were then stored in vials with multiple glass
beads (Microbank; Pro-Lab Diagnostics, Ontario, Canada) at 70°C, subcul-
tured monthly on SDA (Gibco Ltd., Paisley, United Kingdom), and maintained
at 4°C during the experimental period. The purity of the cultures was confirmed
periodically by visualization of Gram-stained organisms and the germ tube test.
Genotypic characterization. (i) Preparation of DNA for randomly amplified
polymorphic DNA (RAPD) analysis. Yeast obtained from stock cultures stored
at70°C was subcultured on yeast-peptone-dextrose medium (1% peptone yeast
extract, 2% glucose, 1.5% agar) at 37°C for 24 h, and single colonies were
transferred to 20 ml of yeast-peptone-dextrose broth (1% peptone, 1% yeast
extract, 2% glucose) and incubated at 30°C under aerobic conditions to the
stationary phase (as assessed by the measurement of the optical density of the
culture at 600 nm). Following incubation, yeasts were harvested by centrifugation
at 4,000  g for 5 min and washed in 1 M sorbitol (dissolved in deionized water).
The yeast pellet was resuspended in 1.5 ml of SE buffer (1.2 M sorbitol, 0.1 M
EDTA [pH 8.0]) containing 3 l of -mercaptoethanol (Sigma Chemical Co., St.
Louis, Mo.) and 0.5 mg of yeast lytic enzyme (Lyticase; Sigma), incubated at 37°C
for at least 1 h until formation of spheroplasts, and harvested by centrifugation
at 2,500  g for 5 min. These spheroplasts were washed twice in SE buffer,
resuspended in 1.5 ml of 0.15 M NaCl–0.1 M EDTA [pH 8.0], lysed by addition
of proteinase K (final concentration, 500 g/ml) and sodium dodecyl sulfate (1%
[wt/vol] final concentration) followed by the addition of RNase (500 g/ml), and
incubated at 55°C for 1 h. The resulting supernatant obtained following centrif-
ugation at 13,000  g was extracted twice with phenol and once with phenol-
chloroform prior to precipitation of DNA by addition of an equal volume of
2-propanol. The DNA precipitated was dissolved in 100 l of TE buffer (10 mM
Tris, 0.1 mM EDTA [pH 8.0]) (6).
(ii) RAPD analysis. Thermocycling was performed in a model PTC-150-16 and
25 minicycler machine (MJ Research, Watertown, Mass.). Fifty microliters of the
PCR master mix containing approximately 200 ng of yeast DNA as template, 5
l of 10 PCR buffer (200 mM Tris-HCl [pH 8.4] and 500 mM KCl), 200 M
deoxynucleoside triphosphates, 25 mM MgCl2, 1 M primer, and 1.5 U of Taq
polymerase (Life Technologies, Gaithersburg, Md.) was used for PCR. The first
five cycles included 30 s of denaturation at 94°C, 2 min of annealing at 52°C
(primer RSD12; 5CCGCAGCCA3) (Life Technologies), and 2 min of primer
extension, followed by 45 cycles of 30 s of denaturation at 94°C, 2 min of
annealing at 57°C (primer RSD12), and 2 min of primer extension at 72°C. The
reaction mixture was held at 72°C for 15 min. Control tubes without template
DNA were included in each run, and reproducibility was checked for each
reaction (19, 51). The PCR products were electrophoresed in an agarose gel
(1.2%) for approximately 2 h at room temperature in TBE buffer (89 mM Tris,
89 mM boric acid, 2.5 mM EDTA [pH 8.0]), stained with ethidium bromide, and
visualized with UV light.
Preparation of Candida inoculum for protein sensitivity tests. The stock cul-
ture of the test yeast isolate was grown on SDA for 18 to 24 h at 37°C. A loopful
of the fresh isolate was inoculated into brain heart infusion broth (Oxoid Ltd.,
Basingstoke, United Kingdom) and grown aerobically at 37°C. After 18 h of
incubation, at the stationary phase of growth, the yeasts were harvested by
centrifugation at 3,500  g for 5 min. The yeast pellet thus obtained was washed
twice by suspension in ice-cold 0.05 mM KCl (which was buffered to pH 7.0 with
KOH) and harvested by centrifugation at 3,500  g for 5 min (50). The yeasts
were resuspended in the buffered KCl to yield a final concentration equivalent to
an optical density of 0.63 to 0.65 at 520 nm (approximately 7 106 cells/ml) using
a UV spectrophotometer (Ultrospec III; Pharmacia LKB, Biochrom Ltd., Cam-
bridge, England).
Human lactoferrin. A stock solution of human apolactoferrin (Sigma) was
used for all susceptibility assays. This solution at a concentration of 2,000 g of
lactoferrin per ml was prepared with sterile distilled water, stored at 4°C, and
used within a week.
Hen egg white lysozyme. Hen egg white lysozyme (Sigma Chemical Co., Poole,
United Kingdom) was used for all experiments. A stock solution of lysozyme
(3,000 g/ml) was prepared with sterile distilled water, stored at 4°C, and used
within a week. The unitary activity of hen egg white lysozyme is half as much as
that of human lysozyme derived from human milk (Sigma Chemical Co., St.
Louis, Mo.).
TABLE 1. Demographic data for patients examined
Patient group and designation Sexa Age(yr)
CDCb classification
of HIV infection
Antifungal agent(s)
given
No. of
visits
Total no. of C. albicans
isolates tested
History of symptomatic oral candidiasis
HK2 M 47 B3 Nystatin 6 16d
HK10 M 36 C3 Ketoconazole; FZc 7 26
HK39 M 34 C3 FZ 6 28
Without symptomatic oral candidiasis
HK1 F 29 A3 8 26
HK4 M 34 B3 7 34
HK5 M 41 A3 5 35
a M, male; F, female.
b CDC, Centers for Disease Control and Prevention.
c FZ, fluconazole.
d From each patient on each visit, 1 to 5 CFU were selected.
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Fungicidal assays. The fungicidal effects of human lactoferrin and lysozyme on
test C. albicans isolates were determined by the method of Soukka et al. (50) with
minor modifications. Test suspensions of 100 l of 200-g/ml human lactoferrin
or of 300-g/ml hen egg white lysozyme and 100 l of the yeast suspension were
dispensed into sterile incubation tubes containing 800 l of 0.05 mM phosphate-
buffered KCl (0.05 mM; pH 7.0) to yield a yeast cell concentration of 5  105/ml.
Thus, the final concentrations of human lactoferrin and lysozyme in the test
suspensions were 20 and 30 g/ml, respectively. These concentrations were
chosen because they were physiologically similar to natural levels in saliva (52,
53). In the control sample, 100 l of sterile distilled water was substituted for the
protein. Both test and control tubes were then incubated at 37°C for 1 h with
gentle shaking. After incubation, the test and control tubes were carefully vor-
texed, 100-l samples were diluted 1:50 and plated on SDA using a spiral plater
(Autoplate 4000; Spiral Biotech, Inc., Bethesda, Md.), and the resultant CFU
were quantified after 48 h of incubation at 37°C. All experiments described above
were conducted on two occasions with quadruplicate samples on each occasion.
Computing the fungicidal value of human lactoferrin (FLF) or hen egg white
lysozyme (FLZ). The fungicidal activity of human lactoferrin (FLF) or lysozyme
(FLZ) was computed using the formula FLF or FLZ  (CFU per milliliter of
control suspension  CFU per milliliter of test suspension)/(CFU per milliliter
of control suspension). Thus, the higher the FLF or FLZ value for a particular C.
albicans isolate, the higher the sensitivity of the yeast to the protein.
Statistical analysis. Statistical analysis was conducted by the Kruskal-Wallis
test (Statistical Package for Social Sciences, version 9; SPSS, Chicago, Ill.) to
determine significant differences in sensitivity to either human lactoferrin or hen
egg white lysozyme between sequential C. albicans isolates from six HIV-infected
patients and the sensitivity of similar or dissimilar genotypes obtained from
individual patients. Spearman correlation analysis was conducted to investigate
the progressive sensitivity of the proteins to different, sequentially isolated ge-
notypes of the same individual.
RESULTS
Patients. The demographic data for the HIV-infected pa-
tient cohort from which the yeasts were isolated are shown in
Table 1. Three of six patients studied had a history of symp-
tomatic oral candidiasis and were managed using nystatin, ke-
toconazole, and fluconazole during the 12-month study period.
The remainder of the cohort did not present with symptomatic
oral candidiasis and were not on antifungals during the study
period.
Genotypes of sequential C. albicans isolates. The RAPD
genotypic profiles of the successive yeast isolates from each
patient were categorized according to different band positions
by visual comparison. For instance, the genotypic profiles of
the 35 sequential C. albicans isolates of patient HK5 are shown
in Fig. 1. Similar differences in genetic profiles were also seen
in the sequential Candida isolates from the remaining five
patients. The isolates from patients HK5 and HK10 elicited the
greatest diversity, with nine genotypes each, while the isolates
from patients HK1 and HK2 elicited the least, with two and
three genotypes, respectively. In general, the identical geno-
type could be consistently isolated from the same patient dur-
ing the 12-month period, while some patients had more than
one. For example, in the case of HK1 a single identical geno-
type was found on five of six sequential visits. Similarly iden-
tical genotypes were recovered on all five visits from HK2 and
on four of seven visits from HK4, and one genotype was re-
covered on six of seven visits and another was recovered on all
seven visits from HK5. Overall, the 50 C. albicans isolates from
the six HIV-infected patients demonstrated remarkable ge-
netic variation, with multiple RAPD profiles.
Fungicidal effect of hen egg white lysozyme on sequential
oral isolates of C. albicans. Exposure to a standard concentra-
tion of hen egg white lysozyme (30 g/ml) indicated that all C.
albicans isolates, irrespective of the genotype, were inhibited
by the protein as indicated by the reduction in CFU in the test
compared with the control cultures. The results of this ly-
sozyme-mediated growth inhibition expressed in terms of the
FLZ value (fungicidal effect of lysozyme) for all 50 sequential
Candida isolates are shown in Table 2. The yeasts demon-
strated a wide range of sensitivity to this enzyme, with an FLZ
range of 0.17 to 0.93. An isolate from patient HK4 (genotype
II; visit 3) was the most susceptible (FLZ  0.93) to lysozyme,
while another from patient HK5 (genotype II; visit 3) was the
least susceptible (FLZ  0.17). On statistical analysis (Kruskal-
Wallis test), there were no significant differences in the sensi-
FIG. 1. RAPD fingerprints of 35 sequential oral C. albicans isolates (obtained during visits 1 to 7) from HIV-infected patient HK5, after
electrophoretic separation generated by amplifying genomic DNA with primer RSD12. Genotypes (a to i) are indicated above the lanes. Sizes of
bands indicate the numbers of base pairs. Lanes M, PCR markers (Sigma).
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tivities to lysozyme between C. albicans isolates of (i) similar
genotypes obtained during sequential visits of individual pa-
tients or (ii) different genotypes obtained from the same pa-
tient on successive visits. However, when the mean FLZ values
of Candida isolates from different individuals were compared,
significant differences were noted (P  0.05).
In addition, we performed Spearman correlation analysis of
the FLZ values of similar genotypes over successive visits. In
the event, genotypes I (six isolates) and II (seven isolates) of a
single patient, HK5, showed a highly significant negative cor-
relation (r  0.88; P  0.02) between sensitivity to lysozyme
and sequential patient visits, implying progressive development
of resistance to the enzyme over the study period.
Fungicidal effect of human lactoferrin on sequential oral
isolates of C. albicans. The results of the fungicidal effect of
human lactoferrin expressed in terms of FLF value (fungicidal
effect of lactoferrin) for the 50 C. albicans isolates obtained
during successive visits of six HIV-infected patients are shown
in Table 3. The isolates demonstrated a wide range of sensi-
tivity (0.09 to 0.85) to human lactoferrin. Of the 50 Candida
isolates tested, the most susceptible (FLF  0.85) was a yeast
isolate from patient HK4 (genotype I; visit 1) and the least
susceptible (FLF  0.09) organisms were isolated from patients
HK5 (genotype II; visit 3) and HK10 (genotype II; visit 3). On
statistical analysis (Kruskal-Wallis test), no significant differ-
ences in the fungicidal values for lactoferrin (FLF) were noted
between (i) C. albicans isolates of similar genotypes obtained
during sequential visits of individual patients or (ii) different
genotypes obtained from the same patient on successive visits.
However, when the mean FLF values of Candida isolates from
different individuals were compared, significant differences
were noted (P  0.05).
Spearman correlation analysis of the FLF values of two dif-
ferent genotypes over successive visits, i.e., genotypes I and II
of a single patient, HK5 (obtained from six and seven sequen-
tial visits, respectively), tended to demonstrate decreasing sus-
ceptibility to human lactoferrin between visits during a 1-year
period of observation. Although this was not statistically sig-
nificant (r  0.78; P 	 0.05), it was notable that the identical
strains showed a highly significant negative correlation be-
tween sensitivity to lysozyme and disease duration (P  0.02;
r  0.88).
DISCUSSION
A number of investigators have reported that Candida spe-
cies from HIV-infected patients with recurrent episodes of oral
thrush are significantly less diverse genetically than commensal
strains from healthy individuals (47, 60). This implies that
strains derived from the same parental stock may persist
TABLE 2. Fungicidal effects of 30 g of hen egg white lysozyme per ml (FLZ) against 50 sequential oral isolates
of C. albicans obtained from six HIV-infected individualsa
Patient
designation Genotype Expt no.
Susceptibility to lysozyme (FLZ)
Patient visit no.
Mean SEM
1 2 3 4 5 6 7
HK1 I 1 0.30 0.29 0.54 0.30 0.26 0.34 0.11
2 0.27 0.29 0.54 0.31 0.25 0.33 0.12
HK2 I 1 0.68 0.53 0.78 0.78 0.80 0.71 0.11
2 0.70 0.53 0.78 0.78 0.80 0.72 0.11
HK4 I 1 0.94 0.73 0.90 0.26 0.71 0.31
2 0.94 0.74 0.89 0.28 0.71 0.30
II 1 0.75 0.69 0.93 0.34 0.68 0.25
2 0.76 0.71 0.94 0.35 0.69 0.25
HK5 I 1 0.64 0.65 0.56 0.40 0.48 0.33 0.51 0.13
2 0.63 0.64 0.59 0.39 0.48 0.35 0.51 0.13
II 1 0.57 0.51 0.17 0.55 0.20 0.32 0.24 0.37 0.17
2 0.55 0.45 0.17 0.56 0.25 0.30 0.28 0.37 0.15
HK10 I 1 0.43 0.47 0.55 0.57 0.51 0.07
2 0.42 0.47 0.54 0.58 0.50 0.07
II 1 0.62 0.44 0.42 0.49 0.11
2 0.63 0.43 0.40 0.49 0.13
III 1 0.67 0.63 0.65 0.03
2 0.66 0.68 0.67 0.01
IV 1 0.71 0.58 0.65 0.09
2 0.70 0.60 0.65 0.07
HK39 I 1 0.51 0.55 0.57 0.90 0.84 0.67 0.18
2 0.51 0.55 0.58 0.90 0.84 0.68 0.18
II 1 0.62 0.83 0.87 0.77 0.13
2 0.64 0.83 0.87 0.78 0.12
Total 0.59 0.14
a Roman numerals designate different genotypes isolated from individual patients. Strains with identical roman numerals from different patients are unrelated.
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through recurrent infections in these immunocompromised pa-
tients. Others have reported similar findings on comparison of
serotypes from immunologically compromised patients (in-
cluding patients with AIDS) and healthy individuals (7).
Although a variety of different DNA typing procedures such
as pulsed-field gel electrophoresis, restriction fragment length
polymorphism, and RAPD analysis have been employed for
deciphering the genetic profiles of individual Candida isolates
by previous workers (34), it appears that the last method is
equally as sensitive as others for this purpose (6, 19). The
RAPD technique requires only a minute quantity of yeast
DNA and is fast and reliable for strain delineation (17, 19).
Hence, in the present investigation we used the RAPD tech-
nique to characterize the genotypic relatedness among the
sequential oral C. albicans isolates from the six HIV-infected
individuals. Prior to choosing the primer RSD12 for the study,
we evaluated others such as RSD6, RSD8, RSD10, and RSD12
(58), and it was observed that the first demonstrated the high-
est discriminatory power in differentiating our collection of
Candida strains into different genotypes. As in similar previous
studies (21), we noted up to five different genotypes from a
single visit. Further, sequential yeast isolates derived from the
same patient yielded similar as well as dissimilar genotypes,
confirming the usefulness of this technique for isotype analy-
ses.
The antifungal effects of both human lactoferrin and hen egg
white lysozyme on Candida were examined according to the
methods described previously by Nikawa et al. (32) and Tobgi
et al. (55), respectively. Our group and others have used these
blastospore susceptibility assays previously (31, 32, 44, 61), and
in the present investigation they once again proved reliable and
sensitive. Using the identical method, Samaranayake et al. (44)
noted the mean (range) FLZ and FLF values of 0.32 (0.27 to
0.36) and 0.34 (0.21 to 0.45), respectively, for five Candida
isolates from healthy individuals. This compares with 0.59 (0.33
to 0.78) and 0.29 (0.17 to 0.58) for lysozyme and lactoferrin,
respectively, for the negative cohort of the present study. Re-
sults indicate a heightened sensitivity of C. albicans to ly-
sozyme, but not lactoferrin, in patients with HIV infection.
However, further studies are warranted to confirm or refute
these findings, due to the small number of isolates tested (five
in total) from the healthy cohort.
In general, the results of the lysozyme assay indicate that
sequential C. albicans isolates from individuals with HIV in-
fection are broadly similar with no significant variability in the
susceptibility of isolates derived possibly from the same paren-
tal stock. Lysozyme is a constituent of saliva with a concentra-
tion range of 1.5 to 57 g of human lysozyme equivalents ml1
(35, 52). The enzyme is present in higher concentrations in
plaque fluid than in whole saliva (9), and activated polymor-
TABLE 3. Fungicidal effects of 20 g of human lactoferrin per ml (FLF) against 50 sequential oral isolates
of C. albicans obtained from six HIV-infected individualsa
Patient
designation Genotype Expt no.
Susceptibility to lactoferrin (FLF)
Patient visit no.
Mean SEM
1 2 3 4 5 6 7
HK1 I 1 0.12 0.22 0.35 0.10 0.13 0.18 0.10
2 0.14 0.22 0.35 0.10 0.14 0.19 0.10
HK2 I 1 0.23 0.14 0.38 0.38 0.63 0.35 0.19
2 0.25 0.15 0.40 0.36 0.61 0.35 0.17
HK4 I 1 0.86 0.67 0.65 0.12 0.58 0.32
2 0.85 0.67 0.63 0.12 0.57 0.31
II 1 0.39 0.34 0.85 0.16 0.44 0.29
2 0.39 0.37 0.84 0.14 0.44 0.29
HK5 I 1 0.31 0.31 0.20 0.17 0.11 0.23 0.22 0.08
2 0.30 0.18 0.24 0.12 0.10 0.22 0.19 0.08
II 1 0.46 0.38 0.10 0.32 0.08 0.16 0.11 0.23 0.15
2 0.45 0.28 0.08 0.36 0.14 0.12 0.14 0.22 0.14
HK10 I 1 0.31 0.16 0.23 0.49 0.30 0.14
2 0.29 0.19 0.28 0.45 0.30 0.11
II 1 0.38 0.29 0.07 0.25 0.16
2 0.38 0.27 0.11 0.25 0.14
III 1 0.12 0.38 0.25 0.18
2 0.13 0.39 0.26 0.18
IV 1 0.13 0.25 0.19 0.08
2 0.11 0.22 0.17 0.08
HK39 I 1 0.36 0.44 0.15 0.13 0.30 0.28 0.13
2 0.38 0.43 0.15 0.14 0.31 0.28 0.13
II 1 0.20 0.12 0.23 0.18 0.06
2 0.18 0.11 0.22 0.17 0.06
Total 0.29 0.12
a Roman numerals designate different genotypes isolated from individual patients. Strains with identical roman numerals from different patients are unrelated.
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phonuclear leukocytes also release this enzyme extracellularly
(20). The antifungal properties of lysozyme are thought to be
mediated through the enzymatic hydrolysis of N-glycosidic
linkages in the microbial cell wall and injury to the cytoplasmic
membrane following direct cationic-protein binding (25). Stud-
ies of the interaction between lysozyme and Candida species
have shown significant inter- and intraspecies variations in
susceptibility to this enzyme (41, 44, 55), and this should be
borne in mind when the results from sequential isolates are
considered.
With regard to lactoferrin, none of the sequential strains in
general demonstrated either increased or decreased suscepti-
bility to the protein to a significant extent during the 12-month
study period. Lactoferrin is found in saliva and other external
secretions such as tears and bronchial secretions (26) and is
also a constituent of the polymorphonuclear leukocytes (4, 27).
The concentration of lactoferrin in unstimulated parotid saliva
is about 7 to 20 g/ml (10, 37) but decreases upon stimulation.
The fungicidal nature of lactoferrin is thought to be due to (i)
sequestration of ferrous ions, leading to deprivation of elemen-
tal iron needed for yeast metabolism (28); (ii) structural
changes induced on yeast cell walls (32); or (iii) the activation
of intracellular autolytic enzyme systems consequential to lac-
toferrin adsorption (16). As with lysozyme, significant inter-
and intraspecies variations in candidal sensitivity to lactoferrin
have been observed previously (32, 44, 50, 61).
Although there were no significant differences in the FLZ
and FLF values of the majority of the sequential isolates, we
noted that in two groups of isolates from patient HK5 belong-
ing to genotypes I (six isolates) and II (seven isolates) the
fungicidal effect of a standard dose of lysozyme, but not lac-
toferrin, significantly and progressively decreased over the 12-
month study period. One explanation for this may be that the
successive generations of Candida in this individual, whose
disease was kept under control by antiretroviral agents, pro-
gressively developed resistance to the nonspecific salivary im-
mune factor lysozyme (r  0.88; P  0.02) during the 12-
month study period. As only 13 of 50 (26%) C. albicans isolates
studied showed the emergence of such resistance to lysozyme,
our data should be interpreted with caution. Nonetheless the
results reported here support the contention that the emer-
gence of these resistant C. albicans strains may perpetuate the
recurrence of oral yeast colonization and infection, a hallmark
of HIV disease. Unfortunately, we were unable to monitor the
temporal variations in salivary lysozyme or lactoferrin concen-
trations in our cohort, although this might have shed further
light on the emergence of resistance. For instance, there are
reports to indicate alterations in major (parotid and subman-
dibular) salivary gland function following HIV type 1 infection
with effects on both the salivary composition and output (flow
rate) (12, 30). Elevated concentrations of lysozyme have been
observed in stimulated as well as unstimulated submandibular
or sublingual saliva (3, 62) and in stimulated parotid saliva (23,
30) from HIV-infected individuals. Kirstila et al. (15) have
reported that all innate, nonimmune salivary defense factors
were equally abundant and present possibly at higher concen-
trations in a group of patients with common variable immuno-
deficiency when compared with age- and sex-matched immu-
nologically competent healthy subjects (15). We previously
reported elevated salivary lysozyme concentrations in mixed
saliva in a Hong Kong cohort of HIV-infected ethnic Chinese
(23% higher than the HIV-free group [P  0.0001] [56]). In
addition, Schiodt et al. (46) demonstrated that patients with
HIV-associated salivary gland disease had increased levels of
lysozyme and salivary IgA and decreased levels of salivary
proteins compared with the HIV-negative controls. Thus, it is
tempting to speculate that the emergence of lysozyme resis-
tance in the small number of Candida isolates reported herein
could be due to an innate rise in salivary lysozyme levels during
HIV disease progression.
With regard to lactoferrin, Muller et al. (30) reported that
the lactoferrin output significantly decreased in a group of 44
subjects with HIV infection in parallel with a markedly re-
duced parotid secretory IgA output. Analysis of a group of
Centers for Disease Control and Prevention stage IV AIDS
patients also showed a decrease in lactoferrin in comparison
with HIV-negative controls (22). Interestingly, Van Der Strate
et al. (57) have observed that, in a group of 15 HIV-infected
subjects, the titers of Candida present in the oral cavity were
unaffected by salivary lactoferrin concentration. Whereas ly-
sozyme levels appear to increase during HIV disease, the re-
verse seems to be the case for lactoferrin, and our results
match these observations, as none of the sequential isotypes
tested showed either a significant increase or a significant de-
crease in sensitivity to lactoferrin over a 12-month period.
To conclude, the present data give us a tantalizing glimpse of
the adaptive responses of oral Candida species to innate anti-
microbial defenses in saliva, such as lysozyme, in HIV infec-
tion. To our knowledge, the present study is the first to report
this phenomenon, and further work is warranted to clarify the
reported findings and elucidate the true role of these and other
oral secretions in chronic oral candidal colonization in patients
with HIV disease.
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